Boston Pharmaceuticals has appointed Santiago Arroyo as chief medical officer and Constantine Chinoporos as chief business officer to further build and develop its portfolio. The company is led by ex- Sanofi CEO Chris Viehbacher and one of Boston's new senior hires comes from the French pharma firm. Chinoporos was previously vice president of globa
By a News Reporter-Staff News Editor at Investment Weekly News POZEN Inc. and Tribute Pharmaceuticals Canada Inc. announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission by Aralez Pharmaceuticals Limited on July 20, 2015, as amended on August 19, 2015 and October 30, 2015, which includes a prox
Ligand Pharmaceuticals Incorporated has announced that it has signed a License Agreement and a Supply Agreement with Vireo Health, LLC granting the latter an exclusive right in certain states within the United States and certain global territories to use Captisol in Vireo's development and commercialization of pharmaceutical-grade...
By a News Reporter-Staff News Editor at Drug Week AbbVie, a global biopharmaceutical company, announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment in non-cirrhotic patients
Deal Type: Partnership Deal Sub Type: Co-Marketing Deal Country: United States of America Deal Status: Completed Deal Value: 0.0000 USD. Accelis Pharma, a specialty pharmaceutical company, has entered into a distribution agreement with Fougera Pharmaceuticals Inc. a company focused on making specialty topical and dermatology medicines and a wholly
ALEXANDRIA, Va., Nov. 27 Alnylam Pharmaceuticals, Cambridge, Massachusetts, and Dana-Farber Cancer Institute, Boston, have been assigned a patent developed by four co-inventors for "compositions and methods for increasing erythropoietin production." The co-inventors are William G. Kaelin Jr., Boston, Victor Kotelianski, Cambridge, Massachusetts,
By a News Reporter-Staff News Editor at Drug Week Flex Pharma, Inc.: Click to Tweet this News Flex Pharma, Inc., a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced at its Investor Day in New York
When William Comanor was casting about for a thesis in the fall of 1961 to complete his Ph.D. in economics at Harvard University, a professor suggested he look into the pharmaceutical industry. Congress, at the time, had been holding hearings on drug manufacturers for more than a year. His landmark paper a year later, "Research and Competitive Prod
By a News Reporter-Staff News Editor at Drug Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventor Ogawa, Kazufumi, filed on May 14, 2007, was published online on November 10, 2015. The patent's assignee for patent number 9180206 is EMPIRE TECHNOLOGY DEVELOPMENT LLC. News editors obtained the following quote from
ALEXANDRIA, Va., Nov. 27 Promentis Pharmaceuticals, Milwaukee, has been assigned a patent developed by four co-inventors for "propionic acids, propionic acid esters, and related compounds." The co-inventors are Michael Neary, West Allis, Wisconsin, Mark A. Wolf, Delanson, New York, Keith D. Barnes, Rexford, New York, and Garry Smith, Royersford,
?Subsequent to its three months ended on September 30, 2015, the Company announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted orphan designation status for the use of the drug Bucillamine for the treatment of cystinuria.? Subsequent to its three months ended on September 30, 2015, the Com
Release date- 24112015- Paris and Tarrytown, New York- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular benefits of Praluent Injection after an acute coronary syndrome.
Deal Type: Venture Financing Deal Sub Type: Start Up Deal Country: United States of America Deal Status: Completed Deal Value: 1.0200 USD. Sermonix Pharmaceuticals, Llc, a specialty pharmaceutical company, has raised USD1.02 million of its planned USD3 million financing round. Index- Women's Health Index- United States of America Index- Osteoporosi
Prior to the recently received Food and Drug Administration approval of the TLC -2000, and the pending Health Canada approval, the sales and marketing teams successfully executed on closing sales for the existing TLC -1000 therapeutic laser technology platform. Now that the TLC -2000 is FDA approved, Theralase will commence building its sales and..
ALEXANDRIA, Va., Nov. 27 The following federal patents were awarded to inventors in New York. ALEXANDRIA, Va., Nov. 27 Promentis Pharmaceuticals, Milwaukee, has been assigned a patent developed by four co-inventors for "propionic acids, propionic acid esters, and related compounds." ALEXANDRIA, Va., Nov. 27 Energizer Brands, St. Louis, has be
ALEXANDRIA, Va., Nov. 27 The following federal patents were awarded to inventors in Pennsylvania. ALEXANDRIA, Va., Nov. 27 Promentis Pharmaceuticals, Milwaukee, has been assigned a patent developed by four co-inventors for "propionic acids, propionic acid esters, and related compounds." ALEXANDRIA, Va., Nov. 27 Belden, St. Louis, has been ass
The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad provides another alternative for a safe and effective influenza vaccine in people 65 years of age and older, said Karen Midthun, M.D., director of the FDA s Center for Biologics Evaluation and Research. Fluad was evaluated
In a significant shift, the Final Guidance allows for a wide array of permissible GE- related claims, even as it confirms FDA s long-held position that such labeling is not mandatory under the Federal Food, Drug, and Cosmetic Act. On the same day, FDA also denied two Citizen Petitions demanding mandatory labeling, took the significant step of appro
ALEXANDRIA, Va., Nov. 27 Vertex Pharmaceuticals, Boston, has been assigned a patent developed by Christopher Young, Sudbury, Massachusetts, for "dosage units of 3- benzoic acid." The patent application was filed on March 19, 2014. Written by Amal Ahmed; edited by Jaya Anand.
Accutest Research Laboratories, a leading independent and internationally accredited Contract Research Organization, has formed a strategic partnership with Fox Chase Cancer Center- Temple Health for joint work on clinical trials. The partnership aims to offer a strategic research platform for Fox Chase Cancer Center- Temple Health and Accutest...
Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both. If the Supreme Court ruling or the November elections mean that all or much of the legislation i
?Zoptrex? recently received DSMB recommendation to continue the ZoptEC Phase 3 clinical program to completion following review of the final interim efficacy and safety data? Zoptrex? met Phase 2 Primary Endpoint in men with heavily pretreated castration- and Taxane-resistant prostate cancer? First patient enrolled in the confirmatory Phas
Release date- 25112015- NEW YORK, NY- Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system diseases, pain and various types of cancer, announces that Kristina M. Capiak, CCRP has been promoted the Company's Vice President of Regulatory Affairs.
By a News Reporter-Staff News Editor at Gene Therapy Weekly Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of neurologic diseases and solid tumor cancers, announced that it has closed a $5 million private placement of convertible notes with new and existing investors. "We are excited by their